ASCO: Aggressive Treatment Common in Terminal Cancer Patients

Share this content:
ASCO: Aggressive Treatment Common in Terminal CA Patients
ASCO: Aggressive Treatment Common in Terminal CA Patients

(HealthDay News) -- Three-quarters of young or middle-aged Americans with terminal cancer receive aggressive treatment during the last month of their lives, according to a study presented at the annual meeting of the American Society of Clinical Oncology, held from June 3 to 7 in Chicago.

Ronald Chen, M.D., M.P.H., an associate professor of radiation oncology at the University of North Carolina in Chapel Hill, and colleagues reviewed claims data for more than 28,000 terminally ill cancer patients younger than 65 who died between 2007 and 2014. The patients lived across 14 different states, and had been diagnosed with advanced lung, colorectal, breast, pancreatic, or prostate cancer. The researchers defined aggressive care as chemotherapy, radiation therapy, hospital/emergency room treatment, admission to an intensive care unit (ICU), or dying in a hospital.

The investigators found that between 71 and 76 percent of patients received some form of aggressive care at the end of life, depending on their type of cancer. Chemotherapy use ranged from 24 to 33 percent; rates of radiation therapy ranged between 6 and 21 percent; between 25 and 31 percent of patients underwent an invasive procedure such as a biopsy or surgery; and about 16 to 21 percent of patients were admitted to the ICU. One-third died in a hospital, while fewer than one in five used hospice care.

"Additional efforts are critically needed to improve end-of-life care for patients with terminal disease, to ensure that the care provided meets the goals and preferences of patients and their families," Chen told HealthDay.

Press Release
More Information

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs